Announcement • Apr 24
OneMedNet Corporation Launches iRWD Platform on Palantir Foundry OneMedNet Corporation announced that its OneMedNet iRWD Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed. Key Commercial Milestones of iRWD Platform: OneMedNet iRWD Platform Now Live on Palantir Foundry. Approximately 70% increase in OneMedNet network, to 80 million patients and 251 million studies. Creating what company believe is the industry's largest network of curated, multi-modal Real-World Data. Creates access to approximately 47 million tokenized patients via Datavant. Enables seamless linkage to complementary datasets including genomics, claims, and mortality data for deeper longitudinal insights. Two new customers contracted for iRWD Platform. With the Palantir-powered iRWD platform now live and fully searchable, OneMedNet is executing its strategy of securing high-margin, annual recurring revenue subscriptions. The Company believes the combination of the new platform capabilities and an expanding customer pipeline positions the Company to convert growing interest into meaningful revenue opportunities. Announcement • Apr 21
OneMedNet Corporation Receives Notice Of Non-Compliance With Minimum Bid Price Requirement For Common Stock On April 14, 2026, OneMedNet Corporation (the Company) received notice (the Notice) from the staff of the Nasdaq Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company, based on the closing bid price of the Company's common stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 12, 2026, to regain compliance with the Bid Price Rule. To regain compliance, the minimum bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period. In the event the Company does not regain compliance with the Bid Price Rule by October 12, 2026, the Company may be eligible for an additional 180-calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Staff will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff will provide notice that its securities will be subject to delisting. The Company intends to continue to actively monitor the bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule, which options may include effecting a reverse stock split, if necessary, to attempt to regain compliance. There can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq Listing Rules. The Company's failure to regain compliance with any Nasdaq Listing Rule could result in delisting. Announcement • Feb 28
Onemednet Corporation Announces Next Phase of Commercial Launch with Its Real-World Data (Rwd) Platform Powered by Palantir Foundry OneMedNet Corporation announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major nations, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generating real-world evidence (RWE). This launch drives rapid expansion of subscription contracts, including multi-year deals representing millions in incremental recurring revenue, with adoption growing across life sciences, AI Health Innovators. As the OneMedNet iRWD™? network scales--with over 2,130 healthcare sites and expanding multimodal data--subscription value rises through greater scale, diversity, real-time access, depth, and insight speed. Customer feedback from evaluations since Fall 2025 confirms the platform's strengths: unmatched analytical depth across integrated clinical/longitudinal datasets; accelerated cohort feasibility and discovery; streamlined intuitive workflows; and faster onboarding of diverse data partners. Commercial launch advances OneMedNet's high-margin recurring revenue model. Evaluation conversions to multi-year subscriptions are happening now, which believe will drive predictable growth and millions in incremental annual recurring revenue (ARR). Network expansion should boost deal sizes and penetration in life sciences/AI/research, fueling sustained bookings. Benefits for Customers: Life sciences teams, health systems, and researchers are expected to gain near real-time access to comprehensive regulatory-grade multimodal RWD; AI-powered search for nuanced insights across clinical and imaging, longitudinal data; faster cohort building/feasibility (we weeks to minutes); and tools enhancing RWE study design, surveys, and evidence generation--accelerating innovation and reducing trial risks. Every dataset integrated into the OneMedNet iR WD platform powered by Palantir Foundy is truly live--continuously connected to its source in real time. This industry-unique capability delivers immense power: subscriptions provide assured, ongoing longitudinal access spanning 20+ years of historical depth and reliably extending 3 years forward, fueling richer, more desirable datasets that drive deeper insights, iterative AI/model development, and sustained evidence generation. 
